
ImpriMed
Palo Alto, CA, United States imprimedicine.com From their website, Nov 2026
Work here? Claim this listing
About
ImpriMed provides AI-driven precision medicine services for veterinary oncology, human blood-cancer oncology, and pharmaceutical CRO clients. It works with veterinarians, physicians, oncologists, and pharmaceutical companies from Palo Alto, California.
Services
Veterinary precision medicine
Provides personalized drug response predictions for canine and feline blood cancers.
Human precision medicine
Predicts patient-specific drug responses using precision analytics for human oncology.
Ex vivo CRO services for pharma
Uses live-cell-based analytics to support oncology drug development programs.
Combination optimization
Ranks synergistic regimens in primary patient cells.
Drug-resistance profiling
Evaluates activity where standard of care fails.
Biomarker validation
Tests candidate markers for use in enrichment rules.
Translational immunotherapy
Measures antigen, engagement, and killing in patient cells.
Flow cytometry panels
Offers add-on flow cytometry panel analysis.
8 more services
- Sequencing and transcriptomics
- Cryopreservation and biobanking
- Personalized prediction profile
- Flow cytometry and CHOP predictions
- Immunoprofile flow cytometry
- PARR
- Multidrug sensitivity genotyping (MDR1)
- Cytology
- Turnaround
- Within 1-2 business days
- What to send
- Single primary patient sample
- Primary patient cells
Capabilities
- Assays and studies
- Flow cytometry
- NGS
- Bispecifics
- ADCs
- Peptides
- Oligonucleotides
14 more
- Small molecules
- Ex vivo drug sensitivity
- Dose-response
- AUC
- E max
- Drug combination synergy
- Synergy scoring
- Antagonism scoring
- Multiparameter flow cytometry
- Drug effect
- Antigen density
- Target engagement
- Malignant vs. normal selectivity
- ML-integrated analysis
- Scale and capacity
- Single primary patient sample
- 20+ drug standard panel
- Therapeutic areas
- Oncology
- Veterinary oncology
- Blood cancers
- Acute myeloid leukemia
- Acute lymphoblastic leukemia
- Non-Hodgkin lymphoma
3 more
- Multiple myeloma
- Myelodysplastic syndromes
- Comparative oncology
Instruments and platforms
- Flow cytometry
Modalities and species
- Modalities
- Small molecule
- Bispecific
- ADC
- Peptide
- Oligonucleotide
- Species and models
- Canine
- Feline
- Primary patient cells
- Primary human cells
- Blood-cancer patient cells
- Blast compartments
3 more
- Stem-cell compartments
- Differentiated compartments
- Immune compartments
Certifications
As the company states them, with the certificate or registry record where there is one.
ISO/IEC 17025Self-reported
CLIASelf-reported
Details
- Type
- CRO
- Quality
- FDA Modernization Act 2.0 (2022) (human-derived, cell-based functional data)
- Based in
- Palo Alto, CA, United States
Public records
- Biocom California CRO directory
- Biomarker Discovery & Validation, Ex vivo drug sensitivity testing, Patient Stratification, Translational Oncology CRO source